Gastrointestinal malignancies harbor actionable MET exon 14 deletions.

Gastrointestinal malignancies harbor actionable MET exon 14 deletions.

Item
http://www.wikidata.org/entity/Q36414027
Single-Center Experience with a Targeted Next Generation Sequencing Assay for Assessment of Relevant Somatic Alterations in Solid Tumors.MET exon 14 deletion (METex14): finally, a frequent-enough actionable oncogenic driver mutation in non-small cell lung cancer to lead MET inhibitors out of "40 years of wilderness" and into a clear path of regulatory approvalGenomic Alterations in Biliary Tract Cancer Using Targeted Sequencing.BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma CellsMET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy.Molecular Testing for Gastrointestinal Cancer.Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion.Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers.Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort.Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges.Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer.Targeted therapies for gastric cancer: failures and hopes from clinical trialsMET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon.MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-LifeOutcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors.MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping.Hypoxia leads to decreased autophosphorylation of the MET receptor but promotes its resistance to tyrosine kinase inhibitors.
P2860

Gastrointestinal malignancies harbor actionable MET exon 14 deletions.

Item
http://www.wikidata.org/entity/Q36414027
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Gastrointestinal malignancies harbor actionable MET exon 14 deletions.
@ast
Gastrointestinal malignancies harbor actionable MET exon 14 deletions.
@en
type
label
Gastrointestinal malignancies harbor actionable MET exon 14 deletions.
@ast
Gastrointestinal malignancies harbor actionable MET exon 14 deletions.
@en
prefLabel
Gastrointestinal malignancies harbor actionable MET exon 14 deletions.
@ast
Gastrointestinal malignancies harbor actionable MET exon 14 deletions.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P932
P356
P1433
P1476
Gastrointestinal malignancies harbor actionable MET exon 14 deletions.
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P932